**Recent advances in the diagnosis and management of Amoebiasis**

Joseph Cooney1,2, Spyros Siakavellas3, Peter L Chiodini4,5, Ula Mahadeva6, Gauri Godbole4, Richard CG Pollok1,2\*¶, Philip J Smith7\*

**\*PJS and RCGP are joint senior authors**

Affiliations:

1Department of Gastroenterology, St George’s Hospital NHS Foundation Trust, London, UK

2Division of Infection and Immunity, St George’s, University of London, UK

3Hepato-Gastroenterology Unit, Hippocration General Hospital of Athens, Greece

4The Hospital for Tropical Diseases, London, UK

5The London School of Hygiene & Tropical Medicine, UK

6Department of Histopathology, Guys and St Thomas’ NHS Foundation Trust, London, UK

7Department of Gastroenterology, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK

**Corresponding author:**

¶Professor Richard CG Pollok, Department of Gastroenterology, St George’s Hospital NHS Foundation Trust, London, UK; Division of Infection and Immunity, St George’s, University of London, UK. Email: richard.pollok@nhs.net

**ORCID iDs:**

Joseph COONEY <https://orcid.org/0000-0002-9295-1625>

Spyros SIAKAVELLAS <https://orcid.org/0000-0001-8217-8950>

Peter L CHIODINI <https://orcid.org/0000-0003-0317-7090>

Ula MAHADEVA <https://orcid.org/0000-0002-9459-3403>

Gauri GODBOLE <https://orcid.org/0000-0002-5846-8517>

Richard CG POLLOK <https://orcid.org/0000-0001-6452-6763>

Philip J SMITH <https://orcid.org/0000-0003-1568-3978>

Conflicts of interest:

PJS is an Honorary Consultant Gastroenterologist at the Royal Liverpool University Hospital and Deputy Editor of Frontline Gastroenterology at the time of submission of this article. He has no other conflicts of interest in relation to this article.

JC, SS, PLC, UM, GG and RCGP declare no conflicts of interest in relation to this article.

**Funding:**

Not applicable

**Author contributions:**

Conception and design: JC, RCGP, PJS; Literature review: JC and SS; initial draft JC, SS, PC, GG, UM, PJS and RCGP. All authors contributed to critical revisions and final draft. PJS and RCGP are the guarantors.

**Acknowledgements:**

We are grateful to the Gastroenterology and Radiology Departments of St George’s Hospital NHS Trust for provision of images included in this article. We thank Guys and St Thomas’ NHS Foundation Trust Histopathology Department for allowing access to histopathology images. We thank CDC (Centers for Disease Control and Prevention, Atlanta, Georgia, USA) for use of their figure on *Entamoeba histolytica* life cycle which we have re-drawn and adapted (Figure 1). The original figure is available free of charge on their website – <https://www.cdc.gov/dpdx/amebiasis/>. Use of this material does not imply endorsement by CDC, ATSDR (Agency for Toxic Substances and Disease Registry, Atlanta, Georgia, USA), HHS (United States Department of Health and Human Services, Washington D.C., USA) or the United States Government.

**Keywords:** Amoebiasis, Entamoeba, Inflammatory bowel disease, colitis, dysentery, diarrhoea, liver abscess

**Word count:** 3982 (excluding abstract, figures and references)

**Provenance:** Commissioned

**Social Media:** @drjosephcooney @RichardPollok @PhilSmithIsBack

**Abstract**

With increasing international travel and migration, tropical and infectious diseases once largely confined to specialist institutes now present more widely. Amoebiasis is a potentially dangerous example, since it may closely mimic the presentation of inflammatory bowel disease. Misdiagnosis and treatment with immunosuppressants can result in fulminant amoebiasis and death. This review considers the epidemiology, pathogenesis, clinical features, diagnosis and treatment of intestinal and extraintestinal amoebiasis. It is written primarily for gastroenterologists, surgeons and acute physicians.

**Background**

*Entamoeba histolytica* is the only species of the protozoal genus *Entamoeba* known to cause the disease known as amoebiasis 1. An estimated fifty million people worldwide are reported to be infected every year with *E. histolytica* and whilst approximately 90% may remain asymptomatic 2 those that do develop symptoms will most commonly suffer bloody diarrhoea (amoebic colitis) and/or liver abscess 3, causing significant morbidity and mortality globally, with 2.2 million disability adjusted life years (DALY) lost and 55,000 deaths per year 4–8. The majority of infections occur in low-income countries, in areas of contaminated water supply and poor sanitation, however, imported cases are increasingly identified in non-endemic regions such as the UK 9. Furthermore, symptoms and clinical features may mimic other conditions, such as inflammatory bowel disease, and in non-endemic regions particularly, misdiagnosis may lead to significant morbidity and in the worst-case scenario, mortality.

At least seven other species of the genus *Entamoeba* have been described: *Entamoeba gingivalis* in the buccal cavity, and six others in the intestine: *Entamoeba coli*, *Entamoeba hartmanni*, *Entamoeba polecki*, *Entamoeba dispar*, *Entamoeba moshkovskii*, and *Entamoeba bangladeshi*. The latter three are morphologically indistinguishable from *E. histolytica* by light microscopy 10. Brumpt first described the existence of both pathogenic and non-pathogenic species of *Entamoeba*, the most prevalent being *E. dispar*1. Now molecular diagnostics can distinguish between *E. histolytica* and non-pathogenic amoebae, allowing precise diagnosis and are considered alongside other contemporary approaches to diagnosis and management of amoebiasis in this review 11–13.

***E. histolytica* – life cycle and pathophysiology**

*E. histolytica* is a single celled anaerobic eukaryote with a two-phase life cycle: infective cyst and invasive trophozoite. Infection begins by ingestion of cysts in food or water contaminated by human faeces. Transmission from animals to humans is thought to be rare 14. Cysts resist host defences by various mechanisms 4,15,16 and upon reaching the terminal ileum they release four trophozoites by the process of excystation 4. The galactose/N-acetylgalactosamine (Gal/GalNAc) specific lectin 17–19 allows trophozoites to adhere to the colonic epithelium and cause tissue injury by: the formation of amoebapores that rupture the host cell; release of cysteine proteases; and induction of an interleukin-1 and interleukin-8 mediated inflammatory response, leading to trophozoite invasion and the formation of pathognomonic flask shaped ulceration in the submucosa 4,15,16. Access to the portal circulation via the gastrointestinal tract permits extra-intestinal dissemination, most commonly leading to liver abscess formation. Trophozoites multiply by binary fission and those in the intestinal lumen encyst again prior to excretion, after which they can survive for up to 90 days 20. It is not known why only a minority develop invasive disease but there is emerging evidence for host genetic susceptibility 15,21. Figure 1, provided by CDC (Centers for Disease Control and Prevention, Atlanta, Georgia, USA), outlines the life cycle of *E. histolytica* 22.

|  |
| --- |
| **Figure 1: Entamoeba histolytica life cycle** |
|  |
| Cysts and trophozoites are passed in faeces image . Cysts are typically found in formed stool, whereas trophozoites are typically found in diarrheal stool. Infection with *Entamoeba histolytica*(and *E. dispar*) occurs via ingestion of mature cysts image from faecally contaminated food, water, or hands. Exposure to infectious cysts and trophozoites in faecal matter during sexual contact may also occur. Excystation image occurs in the small intestine and trophozoites image are released, which migrate to the large intestine. Trophozoites may remain confined to the intestinal lumen (A: non-invasive infection) with individuals continuing to pass cysts in their stool (asymptomatic carriers). Trophozoites can invade the intestinal mucosa (B: intestinal disease), or blood vessels, reaching extraintestinal sites such as the liver, brain, and lungs (C: extraintestinal disease). Trophozoites multiply by binary fission and produce cysts image , and both stages are passed in the faeces image . Cysts can survive days to weeks in the external environment and remain infectious in the environment due to the protection conferred by their walls. Trophozoites passed in the stool are rapidly destroyed once outside the body, and if ingested would not survive exposure to the gastric environment. |
| Source: CDC (Centers for Disease Control and Prevention, Atlanta, Georgia, USA): <https://www.cdc.gov/dpdx/amebiasis/> |

**Epidemiology and travel**

The global prevalence of *E. histolytica* infection23,24 is likely an over estimate due regional endemicity, populations studied and the diagnostic capability to differentiate between non-pathogenic species3. Nonetheless, amoebiasis is a significant global health burden, responsible for 55,000 deaths per year5, predominantly in low income countries (LIC), and particularly in children under 5 years9, where it is a major contributor to parasitic infection-related death and morbidity 5,7. Tropical and subtropical regions of Central and South America, Asia, and Africa are the most widely affected and amoebiasis is most prevalent in Bangladesh, India, Brazil, Colombia, Mexico, and China, and accounts for up to 20–40% reported cases of infectious diarrhoea in some areas of Mexico, Turkey, China, Saudi Arabia, Yemen, Egypt, and South Africa 5,6,23.

Globally, morbidity due to amoebiasis, measured by disability-adjusted life years (DALY), has decreased over the past 30 years due to improved sanitation and medication. However, there has been an interesting trend in high-income countries (HIC), such as North America and Australia, where DALY lost to amoebiasis have increased. This rise is attributed to factors like migration and travel, which have introduced the disease into regions where it was previously uncommon 9. In the UK, *E. histolytica* infection is notifiable by laboratories under the Health Protection Regulations (2010) 25, and approximately 100 infections are reported every year which likely underrepresents the true prevalence 26. The GeoSentinel Surveillance Network data indicate that *E. histolytica* is the third most commonly isolated infection globally among returning tourists who suffer from gastrointestinal disorders, responsible for between 0.3-10% of cases of diarrhoea experienced by visitors 27.

Travel to an endemic area most often precedes infection, with 50% of infections in USA occurring in migrants from Mexico, Central and South America, India and Pakistan 28–30. Similarly in Spain, 46% of infections occurred in migrants and 56% had travelled to an endemic area, most often the Indian subcontinent, South or Central America and sub-Saharan Africa, with travel durations ranging from under 15 days to over 90 days, and symptoms commonly developing after, and not during, the travel period, sometimes developing months or years after exposure 31. Amoebic liver abscess cases have been reported over 20 years after the last visit to an endemic area, suggesting chronic asymptomatic carriage of *E. histolytica* or possibly acquisition in a non-endemic country 32.

**Risk factors *for E. histolytica* infection**

Acquisition in non-endemic countries is well recognised, with an Australian study finding that approximately 8% of infected individuals had no prior travel history 33. Other means of transmission are rare but include transmission following abdominal surgery 34, and after use of contaminated colonic irrigation equipment 35,36. Sexual transmission can also occur. Epidemiological studies from HIC, including USA, Japan, Taiwan, Korea and Australia have shown increased prevalence of *Entamoeba* carriage amongst men who have sex with men (MSM) 37–44. The effect of coexistent HIV infection has also been studied showing higher rates of *E. histolytica* infection in HIV positive MSM, but clinical outcomes appear similar, irrespective of CD4 count 4,29,45–48. Importantly, carriage may occur via a sexual contact who has travelled to an endemic region, and not necessarily via travel by the symptomatic patient.

*E. histolytica* infection affects children and adults equally and can spread within families 4. Studies in adults show a male predominance, especially for amoebic liver abscesses, up to 72-76% of adult cases4,6,29,31,47,49. The reason for this is not known; it may be due to higher alcohol consumption amongst males, with liver injury increasing susceptibility to abscess formation. Post-menopausal women are also at increased risk of liver abscesses; it is speculated hormonal factors in this group may be relevant 4,29. The Monthly Infectious Diseases Surveillance Report produced by Public Health Ontario, Canada, found a peak incidence in men aged 40-49 years and a Japanese review reported a median age of infection of 61 years 29,47. In the USA, amoebiasis related deaths were found to be most prevalent for men over the age of 75 years29.

Immunosuppressive medication, particularly corticosteroids, have been shown to cause increased severity of infection, 50–52. This is particularly concerning, since amoebic colitis may mimic the appearances of inflammatory bowel disease, both symptomatically and endoscopically. A systematic review of 24 cases of amoebic colitis reported that corticosteroid use resulted in rapid progression of disease; with increased rates of colonic perforation, amoeboma formation, rectovaginal fistula and extraintestinal dissemination, requiring more than half to undergo emergency surgery and a quarter resulting in death 52. Two thirds of patients in this case series also received other immunosuppressive mediation including azathioprine, methotrexate, tacrolimus and ciclosporin. Case reports also suggest that anti-tumour necrosis factor-alpha (anti TNF-a) treatment may lead to an increased risk of severe complications 51.

**Clinical features**

90% of patients with *E. histolytica* infection are asymptomatic, and this is likely due to a combination of factors, such as differences in microbiome profile, pro-inflammatory cytokine responses, and formation of antibodies to the parasite’s Gal/GalNAc attachment lectin that influence the host response and clinical disease manifestations 6. 10% of pathogenic cyst carriers develop invasive amoebiasis within 1 year 53 and symptoms of infection will depend on the organ involved, of which the colon and liver are the most commonly affected. Patients with amoebic colitis typically present with a several week history of gradually worsening cramping abdominal pain, weight loss, and watery, mucoid or bloody diarrhoea, making the distinction from inflammatory bowel disease (IBD) especially challenging4,54. Other infectious colitides, such as *Shigella, Salmonella, Campylobacter and* diarrhoeagenic *E. coli* usually have a shorter duration of illness. In a case series from the USA, the median duration of symptoms pre-diagnosis was 14 days, and up to 6 months 46. Table 1 describes the symptoms of amoebic colitis.

|  |  |  |
| --- | --- | --- |
| **Table 1: Symptoms of amoebic colitis**29 | | |
| **Symptoms** | **Prevalence** | |
| **Diarrhoea – watery or bloody**  4,28,31,32,46,54–63 | Very common | >90% |
| **Abdominal pain**  4,28,31,46,54–56,59,62,64–67 | Common | >60% |
| **Fever**  4,46,55,60,63,68 | Less common | <40% |
| **Weight loss**  4,31,54,59 | Uncommon | <25% |
| **Rectal bleeding without diarrhoea**  46,56,68–75 | Rare | |
| **Abdominal mass (amoeboma)**  29,76 | Rare | |

Physical examination may be unremarkable, or may include abdominal tenderness (67%), distension (33%), and very rarely a palpable abdominal mass known as an amoeboma. This is a fibro-inflammatory mass representing chronic infection, typically in the caecum or ascending colon and palpated in the right iliac fossa and can resemble a phlegmon occurring in Crohn’s disease 46. Progression of dysentery to a necrotising or fulminant colitis occurs in 0.5% 45,70,71,77–85. These patients are typically very unwell with fever, bloody diarrhoea, vomiting, and abdominal pain with rebound tenderness 54,86. Three quarters of patients with fulminant amoebic colitis will develop toxic megacolon or perforation 4, with a mortality rate of 40% 54, and the risk is greatest in immunocompromised, alcoholic, diabetic or pregnant patients 86.

There are over 50 case reports published in the last 10 years of atypical colonic presentations, which despite being extremely rare warrant awareness. These include amoebic appendicitis 87–93, peristomal ulceration 74, large bowel obstruction 33,66, gallbladder infiltration 94, perianal ulceration/fistulation 30,95,96, enteric fistulae 95,97,98, and infection residing within 56,75,89,99–101 or appearances mimicking colorectal adenocarcinoma 33,57,76,102–109.

**Amoebic liver abscess**

Amoebic liver abscess (ALA) formation is the most common extra-intestinal manifestation of amoebiasis, affecting 1% of infected individuals 4. On reaching the liver, *E. histolytica* generates an inflammatory reaction which causes hepatocyte necrosis, characteristically leading to the formation of a single, well circumscribed abscess with a rim of connective tissue and containing brown so called “anchovy sauce” pus of dead hepatocytes, a few trophozoites and inflammatory cells 110.

There is significant variability in the onset of symptoms, which usually occur within 8-20 weeks (median 12 weeks) after travel to an endemic region 6,110,111, although there have been case reports of ALA development after more than 20 years 112–114, highlighting the importance of a obtaining a detailed travel history. Symptoms include fever and a dull or aching right upper quadrant pain, which may radiate to the epigastrium, chest, or shoulder 110. Cough and right sided pleural pain may be present when the abscess abuts the diaphragm; jaundice is uncommon and should raise suspicion of an alternative aetiology, particularly if multiple abscesses are present. Only 38% of patients report concomitant diarrhoea 110, and others may report a resolved dysenteric syndrome, but the majority will not have concurrent amoebic colitis with their ALA 115. Physical examination usually demonstrates tenderness over the liver and hepatomegaly in about 50% of cases 4,6,29,116. A more chronic, subtle presentation has also been reported with symptoms of fever, weight loss and abdominal pain developing over months 110 and recurrence of the disease over many years, despite appropriate treatment, may rarely occur 117.

ALA was once a uniformly progressive and fatal disease, but the introduction of effective medical treatment has reduced its mortality rate to 1-3% in uncomplicated cases 4. Prognostic markers for increased mortality include the presence of encephalopathy, hyperbilirubinemia, hypoalbuminemia and increased abscess size 118. Other rare extra-intestinal manifestations may occur, as described in Table 2.

|  |  |  |  |
| --- | --- | --- | --- |
| **Table 2: Rare extra-intestinal manifestations of *E. histolytica* infection** | | | |
| **Site** | **Risk** | **Clinical features** | **Prognosis** |
| **Pulmonary**  119–122 | * Accounts for 2-3% of extraintestinal manifestations * More common when ALA, especially if ruptured * Occurs by haematogenous or lymphatic spread | * Cough * “Anchovy paste” sputum * Haemoptysis * Dyspnoea * Pleuritic chest pain | * Radiology may show elevated right hemidiaphragm and consolidation. * Mortality of >16% * Most respond rapidly to treatment as per ALA |
| **Pericardial**  123,124 | * Very rare * More common when ALA in left hepatic lobe that ruptures | * Chest pain * Pericardial effusion * Acute/constrictive pericarditis * Cardiac tamponade * Congestive cardiac failure | * Left sided ALA drainage is recommended * Pericardiocentesis is recommended |
| **Neurological**  125–127 | * Very rare * Always concomitant ALA * Brain abscesses may be single or multiple | * Brain abscess * Meningoencephalitis * Headache * Vomiting * Impaired mental status * Focal neurological signs | * Fatal if not diagnosed early * CT findings non-specific * Longer treatment durations required, up to 8 weeks * Surgical evacuation may be required |
| **Cutaneous**  30,128 | * Very rare * May occur in isolation or with other organ * Risk from poor perianal hygiene and sexual transmission | * Painful perianal ulceration * Single or multiple erythematous ulcers with well demarcated elevated edges | * Trophozoites may be isolated from ulcer exudate or by scraping ulcer edge * extensive spread may require reconstructive surgery |
| **Genital**  37,42,43,129–132 | * Very rare * risk factor anal sex | * Penile, vaginal and cervical ulcers * Foul smelling vaginal discharge | * Treatment as per other forms * Trace and treat sexual partner |

**Laboratory Diagnosis**

Diagnostic methods comprise faecal microscopy, microscopy of rectal scrapes, serology, histopathology and nucleic acid detection, in support of clinical history, endoscopic and radiological findings. Differentiating *E. histolytica* from the non-pathogenic *E. dispar* is essential for accurate diagnosis and initiation of appropriate treatment. See Table 3 for summary of diagnostic approaches.

Light microscopy of a fresh stool is widely available, inexpensive, quick, can visualise both cysts and trophozoites, and is in common use in LIC. Whilst cysts may be seen in both solid and loose stool, trophozoites will usually only be seen in a loose ‘hot stool’ (a stool which is examined as soon as its produced, ideally within 20 minutes). Staining of a fixed faecal smear, for example with iron haematoxylin, will enable more detailed demonstration of morphology, especially the nucleus. Microscopy may identify ingested erythrocytes within the trophozoite, confirming infection by *E.* *histolytica.* However, it is impossible for morphology to distinguish *E.* *histolytica* cysts from those of non-pathogenic species like *E. dispar* or *E. moskovskii* 115.

Differentiation between *E. histolytica* and *E. dispar* can be made by isoenzyme analysis by starch gel electrophoresis of cultured amoebic trophozoites. However, culture is time consuming, requiring up to 10 days’ incubation, and only successful 50-70% of the time, so these techniques are not used in routine clinical practice 115.

Antigen detection using ELISA (enzyme linked immunosorbent assay) is a simple and readily available technique, using a monoclonal antibody to *E. histolytica* Gal/GalNAc lectin in stool samples and liver abscess aspirate. There are several commercially available laboratory kits available, with reported sensitivities and specificities of over 80% 133.

Molecular approaches are now at the forefront in diagnosis and include DNA amplification tests, using PCR (polymerase chain reaction) and LAMP (loop-mediated isothermal amplification) techniques. These are performed on stool samples or liver abscess aspirate and can accurately differentiate *E.* *histolytica* from non-pathogenic species. Available PCR techniques include conventional, nested, multiplex, and real-time, and target a range of specific genes, such as haemolysin gene (HLY6), which has up to 100% sensitivity and specificity on stool samples. Real-time multiplex stool PCR is now commonplace in HIC and although costly, has the major advantage of being able to detect a wide panel of intestinal pathogens. In the UK, stool PCR enteric panels do not always include *E. histolytica*, and therefore may require a specific request to use a dedicated *E. histolytica* stool PCR assay, which is not widely available in all labs and may need samples to be forwarded to regional laboratories.

Point of care stool testing potentially allows for rapid diagnosis and does not involve expensive laboratory equipment, so may be an option in LIC. There is a range of commercially available kits available, however they have lower sensitivity and specificity and cannot reliably differentiate *Entamoeba* species.

Antibody detection tests measure IgG antibody levels in response to trophozoite antigen and may yield positive results within 7-14 days of symptom onset for both intestinal disease and liver abscess. Various methods are employed, of which ELISA is most commonly available with sensitivity and specificity of over 95% for liver abscess and is useful in non-endemic regions where prior exposure is unlikely. Where available, the amoebic fluorescent antibody test (IFAT) with the cellulose acetate precipitin test (CAP) as a confirmatory assay, is an alternative. Importantly for gastroenterology practice, sensitivity of antibody detection is only around 60% in invasive intestinal amoebiasis. Amoebic serology can remain positive for several years after infection and thus is not suitable for use in endemic regions. Microscopy of liver abscess pus is unhelpful, showing cellular debris, and it is not a sensitive method for diagnosis since trophozoites are seen in less than 20% of cases. Molecular techniques such as PCR can also be performed on aspirated pus.

It is very important to rule out *E. histolytica* infection in all patients with a new or suspected diagnosis of IBD prior to starting immunosuppressive therapies. Where immunosuppression for IBD has to commence urgently and cannot be delayed, testing of a stool by amoebic PCR should be prioritised and treatment reviewed in the light of the result. The most reliable diagnostic test to rule out active infection is to test a single stool for *E. histolytica* using PCR, either as a standalone test or in a pan-enteric panel. Furthermore, a careful travel history should be obtained, since development of disease may post-date initial infection by years. Additional confirmation of the diagnosis can be done by examining the histology of intestinal biopsies (see section on Histopathology) in cases where PCR is not available.

Where available, a full exposure history (travel, sexual contact, clinical reason to suspect amoebic colitis or new diagnosis of IBD) should be provided with the faecal sample, which may otherwise risk rejection by the laboratory, and contact with the microbiology team is recommended to arrange a ‘hot stool’ examination if there is a strong index of suspicion.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Table 3: Laboratory Testing for *E. histolytica*** | | | | | | |
|  | **Specimen** | **Details** | **Sensitivity** | **Specificity** | **Pros** | **Cons** |
| **Light Microscopy** | Stool | Can visualise cysts but cannot differentiate *E. histolytica* from non-pathogenic cysts.  May visualise trophozoites in ‘hot stool’ (stool examined as soon as its produced) | <60% 6 | 95% 134 | Cheap  Widely available  Can screen for other parasites | Low sensitivity and specificity  Stool tests cannot diagnose extra-intestinal infection |
| **Antigen testing ELISA** | Stool or liver abscess aspirate | Test for *E. histolytica* specific antigens | Up to 88% 6 | >80% 6 | Can differentiate *Entamoeba* species  Widely available | Need fresh (not preserved) stool  Reduced sensitivity and specificity once therapy started and for carriers |
| **PCR\*** | Stool and liver abscess aspirate | Test for *E. histolytica* specific genes  Gold standard for intestinal amoebiasis | 92-100% 6 | 89-100% 6 | Can differentiate *Entamoeba* species | Expensive  Requires laboratory skill  *E. histolytica* may not feature in routinely tested pathogen panels |
| **Serology / antibody testing** | Serum | Detects IgG to *E. histolytica* specific antigen | 65-92% 6 | >90% 6 | Useful for both intestinal and extra-intestinal infection | Lower sensitivity for intestinal amoebiasis (~ 60%) than ALA (~95%). Suitable for use in non-endemic regions  False positives in endemic countries  Positive within 7-14 days of symptoms  Can remain positive for years after resolution of infection |
| **Point of Care antigen detection** | Stool | Monoclonal antibody based | 28-100% 115 | 80-100% 115 | Cheap  Quick | Cannot differentiate *Entamoeba* species  Low sensitivity |
| **Histopathology** | Tissue | Light microscopy of formalin-fixed paraffin wax embedded histology specimens, such as colonic biopsies. Trophozoites visible on Haematoxylin & Eosin staining, highlighted by staining with Periodic Acid Schiff (PAS) | Insufficient data | Operator-dependent | Cheap  Routine practice – no requirement for pre-test suspicion  Can be used on tissue from any site, both biopsies and surgical resections can be reported urgently within 24 hrs | Tissue reaction pattern is not specific and can mimic Crohn’s disease. Trophozoites may be missed or misdiagnosed, and identification is operator-dependent |

\*UK Health Security Agency recommend PCR as the method of choice for diagnosis of *E. histolytica* in symptomatic and asymptomatic patients26.

**Colonoscopy**

Although colonoscopy is not mandated for the diagnosis of amoebic colitis, patients with gastrointestinal symptoms, particularly if they are severe or chronic, are often evaluated endoscopically. Both symptoms and endoscopic appearances of amoebic colitis can mimic those seen in IBD in other forms of infectious colitis including intestinal tuberculosis 4,21,47,135. Whilst endoscopic features may be indistinguishable between these conditions; characteristic features of amoebic colitis have been described 47. Amoebic colitis often causes patchy inflammation with or without pale exudate and ulceration, with a predominance in the caecum and ascending colon, since this is likely the site of excystation and trophozoite release, and next most commonly in the rectum, likely due to stasis of stool 47,135,136. Ulcers can range in size and character, from tiny erosions to larger ulcers (>2cm) and are most often multiple and discrete. Surrounding mucosa can appear normal or inflamed. A mucosal “bump” sign has been proposed as a pathognomonic endoscopic feature, consisting of a <1cm inflammatory nodule infiltrated by trophozoites 47. Table 4 and Figure 2 describe the endoscopic features and appearances of amoebic colitis.

There are case reports describing the simultaneous diagnosis of colorectal adenocarcinoma with *E. histolytica* infection on mucosal biopsy 101. However, correlation does not necessarily imply causation.

|  |  |  |
| --- | --- | --- |
| **Table 4: Endoscopic features of amoebic colitis** | | |
| **Feature** | **Site** | **Prevalence** |
| **Erythema/ inflammation**  28,32,46,47,57,59,61,63,65,73,135–137 | Patchy and variable distribution – may be pan-colonic with predominance in caecum and ascending colon | Common (>50%) |
| **Exudate**  32,135,136,138 | Common (>25%) |
| **Ulceration**  32,46,47,57,58,60–65,68,74,76,101,135–144 | Very common (>75%) |
| **Nodule (“bump”)**  32,47,59,136,137 | Rare (5%) |
| **Mass (amoeboma)**  57,67,76,101,136,145 | Most commonly caecum | Very rare (<5%) |
| **Active bleeding**  68 | At site of inflammation/ ulceration | Very rare (<1%) |
| **Stricture**  66,141 | Very rare – case reports of transverse colon | Stricture (<1%) |
| **Coexistent adenocarcinoma**  73,75,101 | Very rare | Very rare (<5%) |

|  |  |  |
| --- | --- | --- |
| **Figure 2: Endoscopic appearances of amoebic colitis** | | |
| A picture containing indoor, doughnut, sitting, donut  Description automatically generated | A picture containing sitting, man, food, holding  Description automatically generated | A picture containing food, sign  Description automatically generated |
| Caecum: mucosal erythema, ulceration, friability and contact bleeding | Transverse colon – superficial ulceration with normal surrounding mucosa | Splenic flexure – deeper ulceration raised edges |
| A close-up of a small intestine  Description automatically generated | Close-up of a human body  Description automatically generated | Close-up of a stomach with a white and green substance  Description automatically generated with medium confidence |
| Caecum: ulcer overlying inflammatory “bump” | Caecum: scattered deep ulceration surrounded by normal mucosa | Caecum: deep ulceration with exudate |

**Histopathology**

|  |  |
| --- | --- |
| **Figure 3: Histopathological findings in amoebic colitis** | |
| A A close-up of a pink and white background  Description automatically generated | Low magnification photomicrograph shows the edge of a typical flask-shaped, undermining ulcer in a colectomy specimen. In biopsies the main pitfall is misdiagnosis as IBD, particularly Crohn’s disease, because the ulceration may be patchy and features of chronicity, such as crypt architectural distortion and fibrosis, may be present. (Haematoxylin & Eosin x 12) |
| B A close-up of a microscope  Description automatically generated | High magnification photomicrograph showing *E. histolytica* trophozoites in ulcer slough on the surface of a colonic biopsy; the erythrophagocytosis is evident. The trophozoites may be mistaken for macrophages or sloughed enterocytes by the inexperienced. (Haematoxylin & Eosin x 200) |
| We thank Guys and St Thomas’ NHS Foundation Trust Histopathology Department for allowing access to histopathology images | |
|  |

**Imaging**

Imaging may be performed alongside laboratory tests to support diagnosis. Plain abdominal radiography may show non-specific features of colitis, with colonic wall thickening, gaseous distension and loss of haustral folds 28. Computed tomography (CT) may help identify features of amoebic colitis, including deep ulceration, patchy distribution of colitis, and omental wrapping 28. CT alone should not be made to diagnose amoebic colitis since features may be indistinguishable from IBD.

CT, magnetic resonance imaging (MRI) and ultrasonography (US) are good modalities to diagnose amoebic liver abscess. It is most commonly unilocular compared with pyogenic abscess, which is most commonly multilocular, but appearances may be indistinguishable. Amoebic liver abscess will appear on US as a cystic intrahepatic hypoechoic lesion with thick walls, often in the right hepatic lobe near the capsule, and by CT there will be a non-enhancing centre with an inflammatory ring following administration of contrast 6,146. The right hemi-diaphragm may be elevated 147. Figure 4 illustrates the typical radiological features of amoebic liver abscess.

|  |  |  |
| --- | --- | --- |
| **Figure 4: Radiological features of amoebic liver abscess in a patient with right upper quadrant pain and weight loss** | | |
| A screenshot of a computer screen  Description automatically generated | A screenshot of a computer  Description automatically generated | A screenshot of a computer screen  Description automatically generated |
| CT abdomen, axial (L) and coronal (R) planes: thick walled homogeneous 7.8cm diameter collection in the right lobe of the liver with surrounding hypo-enhancement and adjacent branch portal venous occlusion. | | US liver: 7.5cmx7cm intrahepatic mass in the right lobe of the liver with mixed internal echogenic and hypoechoic appearances and peripheral blood flow and no internal blood flow. The surrounding liver parenchyma is echogenic, consistent with inflammation. |

**Treatment**

All patients with *E. histolytica* infection should be treated, whether or not they have symptoms. The goal of therapy is to eliminate invading trophozoites and eradicate intestinal carriage. Treatment consists of two agents – a systemically absorbed tissue amoebicide 148, and a luminal amoebicide, to eliminate cysts from the intestinal lumen. Tissue amoebicidal agents are nitroimidazole antibiotics, such as metronidazole and tinidazole, with a Cochrane review finding the latter more effective (metronidazole 5% failure rate vs tinidazole 1% failure rate) with fewer adverse events 24, however tinidazole is no longer available in the UK 149. Alcohol ingestion should be avoided during and for 4 days after metronidazole or tinidazole therapy due to unpleasant disulfiram like side effects. Luminal amoebicides include paromomycin, diloxanide furoate (no longer available in the UK), iodoquinol, and nitazoxanide. Paromomycin, an aminoglycoside which works by disrupting RNA translation, is the agent used in the UK 150,151. Combination therapy has been shown to prevent disease recurrence, so whilst asymptomatic amoebic cyst passage is treated with a luminal amoebicide, treatment of symptomatic amoebiasis requires a tissue amoebicide followed by a luminal amoebicide 24.

Previous national guidelines recommended giving tinidazole or metronidazole, followed by paromomycin 151 . Since 2021, tinidazole has not been available in the UK and therefore metronidazole is recommended 149. Longer duration of treatment is recommended for extra-intestinal amoebiasis, including liver abscess (see Table 5) 6,110. Amoebic liver abscesses do not routinely require percutaneous drainage, but it may be considered if clinical response is not seen after 3 or 4 days medical treatment, or when the abscess is >10cm (which carries an increased risk of abscess rupture) or if the abscess is in the left lobe, where rupture may involve the pericardium 6. The abscess may take many months to resolve fully on imaging, but this does not require extended periods of drug therapy6. Table 5 summarises the treatment for *E. histolytica* infection.

In patients with IBD for which there is a high index of suspicion for amoebiasis, it is reasonable to commence metronidazole therapy once a stool sample has been collected and confirmed to be sent for amoebic stool PCR testing.

Clinical care requires universal enteric precautions which can be discontinued 48 hours after resolution of diarrhoea 26. Both symptomatic and asymptomatic household, co-traveller and sexual contacts (any sexual contact of the case following the suspected time of initial infection, (especially in men who have sex with men) should undergo stool PCR testing and treatment if positive 26. Amoebic clearance should be checked with a stool PCR test at least 1 week following completion of treatment with both tissue and luminal amoebicides26,152. This is done to demonstrate treatment success, although symptomatic relapses after an initial course of treatment are very rare. The literature suggests that asymptomatic carriage persists beyond 15 months after initial identification in untreated individuals 2.

More than 90% of the patients with amoebiasis respond to nitroimidazoles, but parasite persistence is seen in 40-60% patients after nitroimidazole treatment (as they are tissue, not luminal, amoebicides). Luminal amoebicides like paromomycin have up to 85% cure rate in asymptomatic carriers2. A Cochrane review showed reduction in parasitological failure by a third after completion of combination treatment over metronidazole alone (RR 0.36) 24.

Additional, general supportive measures may be required, depending on the patient’s clinical needs and may include intravenous fluids, electrolyte replacement and nutritional supplementation 6. Prevention remains paramount, with personal hygienic measures, avoidance of contaminated food and water supplies, and education regarding sexual transmission 149.

There are currently no licensed vaccines for amoebiasis but the Gal/GalNAc lectin has been the subject of research as a potential antigenic target 145,151. Several novel drug targets involving different amoebic cellular processes have been suggested but these drugs are not yet in routine practice 148. There have been shown to be alterations in the microbiome that may trigger amoebae to switch from commensal bystander to invasive pathogen, raising a theoretical role for probiotics as preventative or adjunctive treatment, but further research in this area is required 145.

**Conclusion**

Misdiagnosis of intestinal amoebiasis as IBD in non-endemic regions can easily occur, be that clinically, endoscopically and histologically, leading to potential inadvertent treatment with steroids or immunosuppressants. This can lead to life-threatening complications and so Gastroenterologists, infectious diseases physicians and surgeons in particular need to have an awareness of it as a potential differential diagnosis. Establishing a detailed life-long travel history is essential, with the diagnosis of intestinal amoebiasis best achieved using stool *E. histolytica* PCR which must be requested specifically. Clinicians should consider routine stool PCR testing for *E. histolytica* in all new IBD cases, especially prior to commencing immunosuppression. Testing should be considered particularly in patients with established IBD who have travelled to endemic areas particularly in the context of a worsening acute colitis. Empirical treatment for amoebiasis should be offered once samples sent if there is a high index of suspicion. Routine colonic histopathology may be diagnostic if trophozoites are present, but sampling error or failure to recognise trophozoites may contribute to low sensitivity overall. If a patient treated for IBD with immunosuppressants fails to improve or deteriorates, it would be appropriate to request review of the histology, to search particularly for trophozoites, if necessary, by a specialist infectious disease histopathologist. Amoebic liver abscess will appear on ultrasound as a cystic intrahepatic hypoechoic lesion with thick walls and on CT there will be a non-enhancing centre with an inflammatory ring following administration of contrast. This should be suspected especially if patients have right upper quadrant pain, fever and deranged liver function tests. Treatment of intestinal amoebiasis should comprise both tissue and luminal amoebicides to avert disease recurrence.

**Key points**

* Clinical, endoscopic and histological misdiagnosis of intestinal amoebiasis as IBD in non-endemic regions can easily occur
* Inadvertent treatment with steroids or immunosuppressants can lead to life-threatening complications
* Diagnosis of intestinal amoebiasis is best achieved using stool *E. histolytica* PCR and needs to be requested specifically, giving full travel history
* Recommend stool PCR testing for *E. histolytica* in all new IBD cases regardless of previous travel history to an endemic area, especially prior to commencing immunosuppression. Testing should be performed in patients with established IBD who have had travel to endemic areas particularly with a worsening colitis. Empirical treatment for amoebiasis should be offered once samples sent if there is a high index of suspicion.
* Routine colonic histopathology may be diagnostic if trophozoites are present, but sampling error or failure to recognise trophozoites may contribute to low sensitivity
* Treatment should comprise both tissue AND luminal amoebicides to avert disease recurrence

**Table Legends**

Table 1: Symptoms of amoebic colitis

Table 2: Rare extra-intestinal manifestations of *E. histolytica* infection

Table 3: Laboratory Testing for *E. histolytica*

Table 4: Endoscopic features of amoebic colitis

Table 5: Treatment for *E. histolytica* infection

**Figure Legends**

Figure 1: *Entamoeba histolytica* life cycle

Figure 2: Endoscopic appearances of amoebic colitis

Figure 3: Histopathological findings in amoebic colitis

Figure 4: Radiological features of amoebic liver abscess in a patient with right upper quadrant pain and weight loss

|  |  |
| --- | --- |
| **Table 5: Treatment for *E. histolytica* infection** | |
| Amoebic colitis 151 | * Metronidazole 800mg TDS PO for 5 days   OR  Tinidazole 2g od for 3 days (no longer available in UK)  *followed by a luminal amoebicide*   * Paromomycin 25 - 35 mg/kg/day in three divided doses PO for 7 days   OR   * Diloxanide furoate for 10 days (no longer available in UK) |
| Amoebic liver abscess | * Metronidazole 800mg TDS PO for 5 to 10 days   OR  Tinidazole 2g od for 5 days (no longer available in UK)  *followed by a luminal amoebicide*   * Paromomycin 25 - 35 mg/kg/day in three divided doses PO for 7 days   OR  Diloxanide furoate for 10 days (no longer available in UK)  ONLY consider drainage of ALA, if:   * Imminent rupture * No clinical response after 3 or 4 days of medical treatment * Abscess diameter > 10cm * ALA in left lobe of liver |
| Extra-intestinal/extra-hepatic amoebiasis | * Consult with Infectious Diseases team |

**References**

1. WHO/PAHO/UNESCO report. A consultation with experts on amoebiasis. Mexico City, Mexico 28-29 January, 1997. *Epidemiol Bull* **18**, 13–14 (1997).

2. Blessmann, J. *et al.* Longitudinal Study of Intestinal Entamoeba histolytica Infections in Asymptomatic Adult Carriers. *J Clin Microbiol* **41**, 4745–4750 (2003).

3. El-Dib N.A. Entamoeba histolytica: an Overview. *Curr. Trop. Med. Rep.* **4**, 11–20 (2017).

4. Stanley, S. L. Amoebiasis. *The Lancet* **361**, 1025–1034 (2003).

5. Lozano, R. *et al.* Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *The Lancet* **380**, 2095–2128 (2012).

6. Shirley D.T., Farr L., Watanabe K., & Moonah S. A review of the global burden, new diagnostics, and current Therapeutics for amebiasis. *Open Forum Infect. Dis.* **5**, ofy161 (2018).

7. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016. *The Lancet Infectious Diseases* (2018).

8. Murray, C. J. L. *et al.* Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *The Lancet* **380**, 2197–2223 (2012).

9. Fu, X. *et al.* Global burden and trends of the Entamoeba infection-associated diseases from 1990 to 2019: An observational trend study. *Acta Tropica* **240**, 106866 (2023).

10. Hooshyar, H., Rostamkhani, P. & Rezaeian, M. An Annotated Checklist of the Human and Animal Entamoeba (Amoebida: Endamoebidae) Species- A Review Article. *Iran J Parasitol* **10**, 146–156 (2015).

11. Petithory, J. C., Brumpt, L. C. & Poujade, F. [Entamoeba histolytica (Schaudinn 1903) and Entamoeba dispar (E. Brumpt 1925) are 2 different species]. *Bull Soc Pathol Exot* **87**, 231–237 (1994).

12. Sargeaunt, P. G., Williams, J. E. & Grene, J. D. The differentiation of invasive and non-invasive Entamoeba histolytica by isoenzyme electrophoresis. *Transactions of the Royal Society of Tropical Medicine and Hygiene* **72**, 519–521 (1978).

13. Tannich, E., Horstmann, R. D., Knobloch, J. & Arnold, H. H. Genomic DNA differences between pathogenic and nonpathogenic Entamoeba histolytica. *Proc Natl Acad Sci U S A* **86**, 5118–5122 (1989).

14. Junaidi, J. *et al.* *Entamoeba histolytica* Neglected Tropical Diseases (NTDs) Agents that Infect Humans and Some Other Mammals: A Review. *E3S Web Conf.* **151**, 01019 (2020).

15. Moonah, S. N., Jiang, N. M. & Petri, W. A. Host Immune Response to Intestinal Amebiasis. *PLoS Pathogens* **9**, (2013).

16. Debnath A., Rodriguez M.A., & Ankri S. Editorial: Recent progresses in amebiasis. *Front. Cell. Infect. Microbiol.* **9**, 247 (2019).

17. Reed, S. L., Keene, W. E. & McKerrow, J. H. Thiol proteinase expression and pathogenicity of Entamoeba histolytica. *J Clin Microbiol* **27**, 2772–2777 (1989).

18. Leippe, M. Amoebapores. *Parasitol Today* **13**, 178–183 (1997).

19. Dodson, J. M. *et al.* Comparison of adherence, cytotoxicity, and Gal/GalNAc lectin gene structure in Entamoeba histolytica and Entamoeba dispar. *Parasitology International* **46**, 225–235 (1997).

20. Marsden, P. D. Clinicai Parasitology, 9th Editon, Beaver, P.C., Jung, R C., Cupp, E. W. Lea and Febiger, Philadelphia, 1984. *Rev. Soc. Bras. Med. Trop.* **17**, 219–219 (1984).

21. Pritt, B. S. & Clark, C. G. Amebiasis. *Mayo Clinic Proceedings* **83**, 1154–1160 (2008).

22. Centers for Disease Control and Prevention (CDC). Amebiasis. https://www.cdc.gov/dpdx/amebiasis/.

23. Nasrallah, J. *et al.* Updates on the worldwide burden of amoebiasis: A case series and literature review. *Journal of Infection and Public Health* **15**, 1134–1141 (2022).

24. Gonzales, M., Dans, L. & Sio‐Aguilar, J. Antiamoebic drugs for treating amoebic colitis. *Cochrane Database of Systematic Reviews* (2019) doi:10.1002/14651858.CD006085.pub3.

25. UK Health Security Agency. UK Health Protection (Notification) Regulations 2010, https://www.legislation.gov.uk/uksi/2010/659.

26. Public Health England. Interim Public Health Operational Guidelines for Amoebiasis v1.0. (2017).

27. Leder, K. GeoSentinel Surveillance of Illness in Returned Travelers, 2007–2011. *Ann Intern Med* **158**, 456 (2013).

28. Kinoo, S. M., Ramkelawon, V. V., Maharajh, J. & Singh, B. Fulminant amoebic colitis in the era of computed tomography scan: A case report and review of the literature. *Sa Journal of Radiology* **22**, a1354 (2018).

29. Kantor M. *et al.* Entamoeba Histolytica: Updates in Clinical Manifestation, Pathogenesis, and Vaccine Development. *Can. J. Gastroenterol. Hepatol.* **2018**, 4601420 (2018).

30. Davis M.J., Templeton S.F., Dickensheets D.L., & Gross A.S. Massive perianal ulceration: Entamoeba histolytica and Candida albicans co-infection. *JAAD Case Rep.* **3**, 553–555 (2017).

31. Roure S. *et al.* Approach to amoebic colitis: Epidemiological, clinical and diagnostic considerations in a non-endemic context (Barcelona, 2007-2017). *PLoS ONE* **14**, e0212791 (2019).

32. Peixoto A., Silva M., Vilas-Boas F., & Macedo G. All that glitters is not gold. A different cause for an ‘ulcerative colitis’. *Rev. Esp. Enferm. Dig.* **109**, 64 (2017).

33. Chahine E. *et al.* Complete resolution of obstructive colonic amebic pseudotumor with conservative treatment: A case report and literature review. *Int. J. Surg. Case Rep.* **59**, 1–3 (2019).

34. Misra, S., Sakhuja, P., Agarwal, A. K. & Javed, A. Fulminant amebic colitis: An unusual postoperative complication of intraabdominal malignancy. *J Postgrad Med* **66**, 99–101 (2020).

35. Istre, G. R. *et al.* An Outbreak of Amebiasis Spread by Colonic Irrigation at a Chiropractic Clinic. *N Engl J Med* **307**, 339–342 (1982).

36. Markell, E. K. The 1933 Chicago outbreak of amebiasis. *West J Med* **144**, 750 (1986).

37. Hung, C.-C., Chang, S.-Y. & Ji, D.-D. Entamoeba histolytica infection in men who have sex with men. *The Lancet. Infectious diseases* **12**, 729–36 (2012).

38. Escolà-Vergé, L. *et al.* Outbreak of intestinal amoebiasis among men who have sex with men, Barcelona (Spain), October 2016 and January 2017. *Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin* **22**, (2017).

39. James, R., Barratt, J., Marriott, D., Harkness, J. & Stark, D. Seroprevalence of Entamoeba histolytica infection among men who have sex with men in Sydney, Australia. *Am J Trop Med Hyg* **83**, 914–6 (2010).

40. Negata, N. *et al.* Risk Factors for Intestinal Invasive Amebiasis in Japan, 2003-2009. *Emerging Infectious Diseases* **18**, 717–724 (2012).

41. Timsit B.L., Deroux A., Lugosi M., Colombe B., & Bouillet L. Amoebosis: May sexual transmission be an underestimated way of contamination? *Rev. Med. Interne* **39**, 586–588 (2018).

42. Billet, A. C., Salmon Rousseau, A., Piroth, L. & Martins, C. An underestimated sexually transmitted infection: amoebiasis. (2019).

43. de Valdoleiros, S. R., Carvalho, J. A., Goncalves, C., Vasconcelos, O. & Sarmento-Castro, R. Nontravel-related invasive Entamoeba histolytica infection with probable heterosexual transmission. *Idcases* **18**, e00592 (2019).

44. Gunther, J., Shafir, S., Bristow, B. & Sorvillo, F. Short Report: Amebiasis-Related Mortality among United States Residents, 1990-2007. *American Journal of Tropical Medicine and Hygiene* **85**, 1038–1040 (2011).

45. Ishioka H., Umezawa M., & Hatakeyama S. Fulminant amebic colitis in an HIV-infected homosexual man. *Intern. Med.* **50**, 2851–2854 (2011).

46. Fleming R. *et al.* Clinical manifestations and endoscopic findings of amebic colitis in a United States-Mexico border city: a case series. *BMC Res Notes* **8**, 781 (2015).

47. Nagata, N. *et al.* Predictive value of endoscopic findings in the diagnosis of active intestinal amebiasis. *Endoscopy* **44**, 425–428 (2012).

48. Samie, A. *et al.* Seroprevalence of Entamoeba histolytica in the context of HIV and AIDS: the case of Vhembe district, in South Africa’s Limpopo province. *Annals of Tropical Medicine and Parasitology* **104**, 55–63 (2010).

49. Acuna-Soto, R., Maguire, J. H. & Wirth, D. F. Gender Distribution in Asymptomatic and Invasive Amebiasis. *American Journal of Gastroenterology* **95**, 1277–1283 (2000).

50. Wang, H. & Kanthan, R. Multiple colonic and ileal perforations due to unsuspected intestinal amoebiasis-Case report and review. *Pathology Research and Practice* **216**, 152608 (2020).

51. Verstockt, B., Vermeire, S., Van Assche, G. & Ferrante, M. When IBD is not IBD. *Scandinavian Journal of Gastroenterology* **53**, 1085–1088 (2018).

52. Shirley, D.-A. & Moonah, S. Fulminant Amebic Colitis after Corticosteroid Therapy: A Systematic Review. *PLoS Neglected Tropical Diseases* **10**, (2016).

53. Gathiram, V. & Jackson, T. F. A longitudinal study of asymptomatic carriers of pathogenic zymodemes of Entamoeba histolytica. *S Afr Med J* **72**, 669–672 (1987).

54. Haque, R. Amebiasis. *N Engl J Med 2003; 348:1565-1573* doi:10.1056/NEJMra022710.

55. Ana Domazetovska *et al.* A 12-Year Retrospective Study of Invasive Amoebiasis in Western Sydney: Evidence of Local Acquisition. (2018).

56. Cooper, C. J., Fleming, R., Boman, D. A. & Zuckerman, M. J. Varied Clinical Manifestations of Amebic Colitis. *Southern medical journal* **108**, 676–81 (2015).

57. Bronswijk M. & Van Gool S. A case of amoebic colitis with amoeboma and simultaneous liver abscesses. A diagnosis by colonoscopy. *Acta Gastro-Enterol. Belg.* **82**, 539–541 (2019).

58. Young C.A., Gracie D.J., Subramanian V., & Wyatt J.I. Amoebic colitis. *Diagn. Histopathology* **23**, 563–565 (2017).

59. Mogensen, T. H., Christiansen, J. J., Eivindson, M. V., Larsen, C. S., & JOUR. Misdiagnosed amoebic colitis leading to severe dysentery and necrotizing colitis-Report of a case and review of the literature. (2014).

60. Upadhyay, R., Gupta, N., Gogia, P. & Chandra, S. Poached egg appearance in intestinal amebiasis. *Gastrointestinal endoscopy* **76**, 189–90 (2012).

61. Den Y., Kinoshita J., Deshpande G.A., & Hiraoka E. Amoebiasis masquerading as inflammatory bowel disease. *BMJ Case Rep.* **2015**, A1708 (2015).

62. Debourdeau, A., Boivineau, L. & Iltache, S. The Little Beast That Pretended to Be a Severe Crohn’s Disease. *Gastroenterology* **157**, 1483–1484 (2019).

63. Kahn T., Locketz M., & Thomson S. The value of microscopy in the diagnosis of colitis. *S. Afr. Gastroenterol. Rev.* **17**, 27–29 (2019).

64. Vinnamala S., Arasaradnam R., Malik A., S., S., & Mannath J. All caecal ulcers is not crohn’s: Think travel-think again. *Acta Gastro-Enterol. Belg.* **80**, 83–84 (2017).

65. Li N., Wang H.-H., Zhao X.-J., & Sheng J.-Q. Amebic colitis: Colonoscopic appearance. *Endoscopy* **47**, E145–E146 (2015).

66. Varshney V.K., Soni S.C., Yadav T., Puranik A., & Elhence P. Amebic colonic stricture: An unusual presentation. *Trop. Parasitol.* **8**, 98–100 (2018).

67. Wang S.-Y. *et al.* Ameboma mimicking submucosal tumor of the colon in an elderly. *Int. J. Gerontol.* **5**, 126–128 (2011).

68. Dogra V.K., Gupta D., Kashyap R., Nand L., & Sondhi S. Intestinal amebiasis presenting as life threatening lower GI bleed-A rare presentation. *Ann. Trop. Med. Public Health* **10**, 244–246 (2017).

69. Madden G.R., Shirley D.-A., Townsend G., & Moonah S. Case report: Lower gastrointestinal bleeding due to Entamoeba histolytica detected early by multiplex PCR: Case report and review of the laboratory diagnosis of amebiasis. *Am. J. Trop. Med. Hyg.* **101**, 1380–1383 (2019).

70. Atif Khan M., Verma G.R., & Lokesh H.M. Fulminant amebic colitis with lower GI bleed with liver abscess. *Int. J. Colorectal Dis.* **25**, 535–537 (2010).

71. Chandnani, S. *et al.* Massive Lower Gastrointestinal Bleeding Due to Fulminant Necrotizing Amebic Colitis: A Diagnostic and Therapeutic Challenge. *The Journal of the Association of Physicians of India* **67**, 79–81 (2019).

72. de Leijer J.H., Tan A.C.I.T.L., Mulder B., & Zomer S.F. Unexpected amebic colitis presenting with rectal bleeding and perforation after biopsy. *Gastrointest. Endosc.* **88**, 565–566 (2018).

73. Ito S. *et al.* A case of a rectal adenocarcinoma mimicking a neuroendocrine tumor in the background mucosa of amoebic colitis. *Clin. J. Gastroenterol.* (2020) doi:10.1007/s12328-019-01088-1.

74. Sasaki, Y., Yoshida, T., Suzuki, J., Kobayashi, S. & Sato, T. [A Case of Peristomal Cutaneous Ulcer Following Amebic Colitis Caused by Entamoeba histolytica]. *Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases* **90**, 73–6 (2016).

75. Goel, P. *et al.* Entamoeba histolytica: A surprising coexistence with adenocarcinoma - Never brush aside brushings for biopsy. *Journal of Laboratory Physicians* **10**, 251–254 (2018).

76. Li A.A., Cholankeril G., Berry G.J., & Fernandez-Becker N. An Unexpected Colonic Mass. *Am. J. Gastroenterol.* **114**, 180–181 (2019).

77. Desai P. & Sivaramakrishnan N. Acute fulminant necrotizing amoebic colitis: A potentially fatal cause of diarrhoea on the Acute Medical Unit. *Acute Med.* **10**, 145–148 (2011).

78. Ortiz-Castillo F. *et al.* Amoebic toxic colitis: Analysis of factors related to mortality. *Pathog. Global Health* **106**, 245–248 (2012).

79. Wingfield, T. *et al.* Closing The Brief Case: A Rare Case of Invasive Amebiasis Requiring Emergency Subtotal Colectomy in an HIV-Positive Man. *Journal of clinical microbiology* **56**, (2018).

80. Kenyon, C. & Otto, M. Bowel ‘infarction’ in a postpartum patient. *Clin Infect Dis* **53**, 914–2 (2011).

81. Badyal R.K., Gupta R., & Vaiphei K. Diffuse perforated necrotising amoebic colitis with histoplasmosis in an immunocompetent individual presenting as an acute abdomen. *BMJ Case Rep.* 009059 (2013) doi:10.1136/bcr-2013-009059.

82. Kawazoe, A. & Nagata, N. Fulminant amebic colitis with an atypical clinical presentation successfully treated by metronidazole. *Clin Gastroenterol Hepatol* **10**, e91 (2012).

83. Morris, P. D., Lee, D., Chung, K. K.-Y., Shin, J.-S. & Byrne, C. Fulminant amoebic colitis and septic shock in a returning traveller. *ANZ J Surg* **89**, E50 (2019).

84. Arvind M., Nijhar J.S., & Ramasamy P. Fulminant necrotising amoebic colitis: A diagnostic conundrum. *Med. J. Malays.* **70**, 365–366 (2015).

85. The Brief Case: A Rare Case of Invasive Amebiasis Requiring Emergency Subtotal Colectomy in an HIV-Positive Man. *Journal of Clinical Microbiology* **56**, (2018).

86. Chaturvedi R., Gupte P.A., & Joshi A.S. Fulminant amoebic colitis: A clinicopathological study of 30 cases. *Postgrad. Med. J.* **91**, 200–205 (2015).

87. Singh N.G., Rifat Mannan A.A.S., & Kahvic M. Acute amebic appendicitis: Report of a rare case. *Indian J. Pathol. Microbiol.* **53**, 767–768 (2010).

88. Kishore M., Chauhan D.S., Rahar S., & Singh S. Acute amoebic appendicitis: A rare case report. *J. Clin. Diagn. Res.* **12**, ED01–ED02 (2018).

89. Ito D. *et al.* Amebiasis presenting as acute appendicitis: Report of a case and review of Japanese literature. *Int. J. Surg. Case Rep.* **5**, 1054–1057 (2014).

90. Herrera, G. C. *et al.* Amebiasis, a rare cause of acute appendicitis. *Journal of Surgical Case Reports* rjz076 (2019) doi:10.1093/jscr/rjz076.

91. Ichikawa H. *et al.* Amoebiasis presenting as acute appendicitis. *Tokai J. Exp. Clin. Med.* **41**, 227–229 (2016).

92. Norwich, I. & JOUR. Amoebiasis presenting as acute appendicitis. (2019).

93. Taiichiro Kobayashi *et al.* Underestimated Amoebic Appendicitis among HIV-1-Infected Individuals in Japan. *Journal of clinical microbiology* **55**, 313–320 (2016).

94. Ouadi, Y. *et al.* Amoeboma of the gallbladder mimicking a cholangiocarcinoma: A case report. *International Journal of Surgery Case Reports* **110**, 108656 (2023).

95. Takahashi T. & Iwamoto A. Perianal fistula caused by intestinal invasive amebiasis in a male patient with AIDS. *J. Exp. Clin. Med.* **5**, 237–238 (2013).

96. Agrawal V., Garg P.K., Jain B.K., Mishra K., & Mohanty D. Amoebic anal fistula: new insight into an old disease. *Acta Med Indones* **46**, 131–133 (2014).

97. Jones, O. P., Murphy, J. A., Hamid, B. N. & Vimalachandran, D. Colocutaneous fistula secondary to amoebiasis. (2010).

98. Dinner, M. & JOUR. INTERNAL INTESTINAL FISTULAE CAUSED BY AMOEBIASIS. (2018).

99. Ayari, H. *et al.* [Colonic amoebiasis simulating a cecal tumor: case report]. *Medecine et sante tropicales* **23**, 274–5 (2013).

100. Grosse, A. Diagnosis of colonic amebiasis and coexisting signet-ring cell carcinoma in intestinal biopsy. *World Journal of Gastroenterology* **22**, 8234–8234 (2016).

101. Gupta, P., Sahay, A., Ramadwar, M. & Saklani, A. Entamoeba Histolytica Infesting Colonic Malignancy: First Series of Four Cases. (2018).

102. Al Rehily S., Kaki R., Al Ghamdi F., & El-Hossary D. Amoeboma in a Saudi resident: A case report. *JMM Case Rep.* **3**, (2016).

103. Saha, K., Sengupta, M., Mitra, S. & Ray, S. Amoeboma of colon mimicking colonic carcinoma. *Trop. parasitol.* **4**, 122–4 (2014).

104. Boopathy V., Alexander T., Balasubramanian P., & Phansalkar M. Amoeboma: Resurfacing of a vanishing illness. *BMJ Case Rep.* (2014) doi:10.1136/bcr-2013-202616.

105. Sinharay, R., Atkin, G., Mohamid, W. & Reay-Jones, N. Caecal amoebic colitis mimicking a colorectal cancer. *J. surg. case rep.* **2011**, 1 (2011).

106. Mishra A. *et al.* Right abdominal mass: Keep an open mind. *Libyan J. Med.* **5**, 1–3 (2010).

107. Rodrigues G. Simultaneous occurrence of amoebic liver abscess and cecal ameboma. *J. Infect. Public Health* **9**, 356–357 (2016).

108. Takashima, M. *et al.* Synchronous tumor with diffuse large B-cell lymphoma and ameboma. *J Clin Oncol* **29**, e769-71 (2011).

109. Higami, S. *et al.* The first case of huge amebic intra-abdominal tumor with asymptomatic amebic colitis. *Surg Case Rep* **1**, 48 (2015).

110. Wuerz, T. *et al.* A review of amoebic liver abscess for clinicians in a nonendemic setting. *Canadian Journal of Gastroenterology and Hepatology* **26**, 729–733 (2012).

111. Sinha, M. K. Amebic Liver Abscess: Varied Presentation and Management Update. *International Journal of Scientific Study* **4**, 99–102 (2016).

112. Nespola, B. *et al.* First case of amebic liver abscess 22 years after the first occurrence. *Parasite* **22**, 30 (2015).

113. Patel T.R., Grams D., Alrabaa S., & Sinnott J. Delayed Diagnosis of Amoebiasis. *Clin. Microbiol. Newsl.* **34**, 106–107 (2012).

114. Lachish, T., Wieder-Finesod, A. & Schwartz, E. Amebic Liver Abscess in Israeli Travelers: A Retrospective Study. *The American Journal of Tropical Medicine and Hygiene* **94**, 1015–1015 (2016).

115. Saidin, S., Othman, N. & Noordin, R. Update on laboratory diagnosis of amoebiasis. *European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology* **38**, 15–38 (2019).

116. Banurekha, R. A Prospective Study on Incidence, Etiopathogenesis, Clinical Presentation, Management and Prognosis of Liver Abscess. (2013).

117. Singal, D. K., Mittal, A. & Prakash, A. Recurrent amebic liver abscess. *Indian J Gastroenterol* **31**, 271–3 (2012).

118. Anesi, J. A. & Gluckman, S. Amebic liver abscess. *Clinical Liver Disease* **6**, 41–41 (2015).

119. Shrestha M., Shah A., & Lettieri C. Dyspnea and dysentery: A case report of pleuropulmonary amebiasis. *South. Med. J.* **103**, 165–168 (2010).

120. Talukdar A., Mukherjee K., Khanra D., & Saha M. An unusual cause of haemoptysis: A diagnostic challenge for clinicians. *BMJ Case Rep.* (2012) doi:10.1136/bcr-2012-006751.

121. Chang, H.-R., Lee, J.-J. & Lin, C.-B. Pleural Empyema Secondary to Rupture of Amoebic Liver Abscess. *Internal Medicine* **51**, 471–474 (2012).

122. Sarkari, B., Hosseini, G., Motazedian, M. H., Fararouei, M. & Moshfe, A. Prevalence and risk factors of intestinal protozoan infections: a population-based study in rural areas of Boyer-Ahmad district, Southwestern Iran. *BMC Infect Dis* **16**, 703 (2016).

123. Murali A., Balu K., Paari V., & Rajendiran G. Atrial flutter and pericarditis - A rare complication of right lobe amoebic liver abscess. *Med. J. Malays.* **66**, 499–500 (2011).

124. Agarwal A. *et al.* Amoebic cardiac tamponade. *QJM* **112**, 709–710 (2019).

125. Jindal, A. *et al.* Amoebic Cerebral Abscess: Still A Diagnostic Dilemma with Fatal Outcome. (2019).

126. Maldonado-Barrera C.A. *et al.* Clinical case of cerebral amebiasis caused by E. histolytica. *Parasitol. Res.* **110**, 1291–1296 (2012).

127. Petri W.A. & Haque R. Entamoeba histolytica brain abscess. *Handb. Clin. Neurol.* **114**, 147–152 (2013).

128. Verma G.K. *et al.* Amoebiasis cutis: Clinical suspicion is the key to early diagnosis. *Australas. J. Dermatol.* **51**, 52–55 (2010).

129. Abdolrasouli, A. *et al.* Sexually transmitted penile amoebiasis in Iran: a case series. (2012).

130. Prasetyo, R. H. Scrotal abscess, a rare case of extra intestinal amoebiasis. *Tropical biomedicine* **32**, 494–6 (2015).

131. Ahuja, N. K. *et al.* Esophageal distensibility measurement: impact on clinical management and procedure length. *Diseases of the Esophagus* **30**, 1–8 (2017).

132. Mukherjee S., Nagarsenkar A., Chandra S., Sahasrabhojanee M., & Sawant D. Amoebic cervicitis mimicking posterior wall fibroid: A rare presentation. *J. Microbiol. Immunol. Infect.* **47**, 354–357 (2014).

133. Haque, R. *et al.* Diagnosis of Amebic Liver Abscess and Intestinal Infection with the TechLab Entamoeba histolytica II Antigen Detection and Antibody Tests. *Journal of Clinical Microbiology* **38**, 3235–3239 (2000).

134. Mohanty, S., Sharma, N. & Deb, M. Microscopy versus enzyme linked immunosorbent assay test for detection of Entamoeba histolytica infection in stool samples. *Trop Parasitol* **4**, 136 (2014).

135. Horiki, N. *et al.* Endoscopic findings and lesion distribution in amebic colitis. *Journal of Infection and Chemotherapy* **21**, 444–448 (2015).

136. Lee K.-C., Lu C.-C., Hu W.-H., Lin S.-E., & Chen H.-H. Colonoscopic diagnosis of amebiasis: a case series and systematic review. *Int. J. Colorectal Dis.* **30**, 31–41 (2014).

137. Legris T. *et al.* Ameboma: An unusual cause of gastrointestinal bleeding during severe leptospirosis. *BMC Infect. Dis.* **14**, 299 (2014).

138. Okamoto, M. *et al.* Amebic colitis in asymptomatic subjects with positive fecal occult blood test results: clinical features different from symptomatic cases. *Am. J. Trop. Med. Hyg.* **73**, 934–935 (2005).

139. Singh, R., Balekuduru, A., Simon, E., Alexander, M. & Pulimood, A. The differentiation of amebic colitis from inflammatory bowel disease on endoscopic mucosal biopsies. *Indian J Pathol Microbiol* **58**, 427 (2015).

140. Wu, N. & Freiman, J. S. Caecal ulceration in an asymptomatic man. *Gut* **66**, 886 (2017).

141. Christopher Skappak *et al.* Invasive Amoebiasis: A Review of Entamoeba Infections Highlighted with Case Reports. (2014).

142. Yoon E.W.T. & Sumii M. Severe amoebic colitis in an HIV-infected male patient. *BMJ Case Rep.* **2016**, 218570 (2016).

143. Watanabe, K. *et al.* Asymptomatic Intestinal Amebiasis in Japanese HIV-1–Infected Individuals. *The American Journal of Tropical Medicine and Hygiene* **91**, 816–816 (2014).

144. Ng C.H., Lai L., Ng K.S., & Li K.K. Relapse of amoebic infection 10 years after the infection. *Hong Kong Med. J.* **17**, 71–73 (2011).

145. Cacheux W. *et al.* Amoebic abscess diagnosed on fluorodeoxyglucose positron emission tomography scan in patient with recurrent oropharyngeal squamous cell carcinoma. *J. Clin. Oncol.* **29**, e365–e366 (2011).

146. Pablo Rodríguez Carnero, Paula Hernández Mateo, Susana Martín-Garre, Ángela García Pérez, & Lourdes del Campo. Unexpected hosts: imaging parasitic diseases. (2017).

147. Jesrani, G., Kaur, J., Gupta, S., Cheema, Y. & Ahlawat, P. Mediastinal extension of amoebic liver abscess: A case report on the rare thoracic complication of Entamoeba histolytica. *Turk J Emerg Med* **23**, 250 (2023).

148. Shrivastav, M. T., Malik, Z., & Somlata. Revisiting Drug Development Against the Neglected Tropical Disease, Amebiasis. *Front. Cell. Infect. Microbiol.* **10**, 628257 (2021).

149. NICE. Trichomoniasis: Changes, Last revised in November 2023. *National Institute of Clinical Exellence* https://cks.nice.org.uk/topics/trichomoniasis/how-up-to-date-is-this-topic/changes/#:~:text=Recommendations%20relating%20to%20tinidazole%2C%20and,been%20discontinued%20in%20the%20UK. (2024).

150. Morán, P. *et al.* Amoebiasis: Advances in Diagnosis, Treatment, Immunology Features and the Interaction with the Intestinal Ecosystem. *IJMS* **24**, 11755 (2023).

151. Richardson, D. *et al.* British Association of Sexual Health and HIV (BASHH) United Kingdom national guideline for the management of sexually transmitted enteric infections 2023. *Int J STD AIDS* **34**, 588–602 (2023).

152. Public Health England. Principles and Practice Recommendations for the Public Health Management of Gastrointestinal Pathogens, A joint guidance from Public Health England and the Chartered Institute of Environmental Health. (2019).